Topotecan HCl

Catalog No.S1231 Synonyms: NSC609699, Nogitecan HCl, SKFS 104864A

Topotecan HCl Chemical Structure

Molecular Weight(MW): 457.91

Topotecan HCl is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 180 In stock
USD 320 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Cells were treated at the same concentrations as in Caspase3/7 assay for 16 hours and total cell lysates were prepared for Western blotting. GAPDH was used as a loading control.

    BMC Cancer, 2015, 10.1186/s12885-015-1231-z. Topotecan HCl purchased from Selleck.

    Pax3:Foxo1a knockdown increases select chemotherapy sensitivities. MTS assay was performed for Pax3:Foxo1a knockdown mouse aRMS tumor cells treated with DNA damaging agents and microtubule inhibitors. Pax3:Foxo1a knockdown reduced the concentration at which viability was impaired by 50% (IC50) of topotecan by 4.8 fold, respectively, yet did not affect the IC50 of mafosfamide.

    PLoS Genet 2014 10(1), e1004107. Topotecan HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Topotecan HCl is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively.
Features Topotecan is a water-soluble derivative of camptothecin.
Targets
Topo I (DU-145 Luc cells) [1]
(Cell-free assay)
Topo I (MCF-7 Luc cells) [1]
(Cell-free assay)
2 nM 13 nM
In vitro

Stronger drug activity of Topotecan is observed for DU-145 Luc and MCF-7 Luc cells. [1] Topotecan causes cytotoxicity during the course of DNA replication by stabilizing the covalent complex between topoisomerase I and DNA and preventing the religation of enzyme-linked single-strand DNA break. Topotecan stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage acute lymphoblastic leukemia (ALL) cells, causes rapid apoptotic cell death despite high-level expression of bcl-2 protein, and inhibits ALL cell clonogenic growth in a dose-dependent fashion. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-435 cells MoT2R5l1d3SxeHnjxsBie3OjeR?= NYjFRZBPPzJiaB?= M{C3XGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20N|Uh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygbYM2OD1zIH7N MYSyNFM4OTF6Mx?=
human Bel7402 cells MWTDfZRwfG:6aXRCpIF{e2G7 M4LVTlk3KGh? M2L3[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJmdDd2MEKgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yNjJibl2= NWDLS21vOTVzNkWxOFQ>
human HCT8 cells NXfpeG9MS3m2b4TvfIlkyqCjc4PhfS=> M2\oelk3KGh? NWO3ZohXS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWODDj[YxteyCjZoTldkA6PiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVEvPSCwTR?= NI\BfosyPTF4NUG0OC=>
human MCF7 cells NWXJN28zS3m2b4TvfIlkyqCjc4PhfS=> M{Oyflk3KGh? MkDGR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGuPEBvVQ>? NHX5V3MyPTF4NUG0OC=>
human A549 cells MnW3R5l1d3SxeHnjxsBie3OjeR?= NU[5eoNuQTZiaB?= MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;Mz6yJI5O MWmxOVE3PTF2NB?=
human colon carcinoma SW620 cell MmXjR5l1d3SxeHnjxsBie3OjeR?= MoTqR5l1d3SxeHnjJJBwfGWwdHnheIlwdiCxZjDUc5BwfGWlYX6gLHRRMSCkeTD0bIUh[2:vcH;1coQhcW5iaIXtZY4h[2:ub36gZ4Fz[2mwb33hJHNYPjJyIHPlcIwhdGmwZTygTWM2OD1|LkKgcm0> NEe5dpQyOjRyOEewOy=>
human MESSA cells NFvlNFVEgXSxdH;4bYPDqGG|c3H5 MUi3NkBp NW\sOpRZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVU1GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwQVQhdk1? NGThS4MzOTN2MU[3OC=>
human BGC823 cells NVS5PWpRS3m2b4TvfIlkyqCjc4PhfS=> MmSyPVYhcA>? NXiyR5d[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkeFOEKzJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PC5|IH7N MmrDNVUyPjVzNES=
human Ketr3 cells M1HxPGN6fG:2b4jpZ:Kh[XO|YYm= M3:wbFk3KGh? NWnad|F2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU2W2ckOgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF01Njlibl2= NHXnU|AyPTF4NUG0OC=>
LOX cells M3rPW2N6fG:2b4jpZ:Kh[XO|YYm= MVTDfZRwfG:6aXPpeJkhf2G|IHTleIVzdWmwZXSgbY4hfmm2cn:gbY4hVE:[IHPlcIx{KCivZXzhco9u[Slib3[gbJVu[W5idIXtc5Ih[2WubDDsbY5meyCkeTD1d4lv\yCPVGSgZZN{[XluIFnDOVA:PSCwTR?= M33tdFc5PTN|M{G=
human A549 cells M2OzfmZ2dmO2aX;uJIF{e2G7 NWrIWXd1PCCq MnTLRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PSCwTR?= NIj5WVIyQDJyN{e0PC=>
human H69 cells MUfDfZRwfG:6aXRCpIF{e2G7 MXq3NkBp MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOlkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR|UxRTZibl2= MUiyNVM1OTZ5NB?=
human A2780 cells NH20W2ZEgXSxdH;4bYPDqGG|c3H5 M1rEVlczKGh? M3X2emN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KG:4ZYLlfJBz\XO|aX7nJIFteGijNXLleIE{KGmwdHXndolvKGG|c3Xzd4VlKGG|IHPlcIwhe3W{dnn2ZYwh[W[2ZYKgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME22JI5O MVmyNlk2QTJ2Nh?=
human LNCAP cells NXPORlAxS3m2b4TvfIlkyqCjc4PhfS=> MWC3NkBp NILOPZdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVkODUDDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUC9PUBvVQ>? NV3FbmJ5OjF|NEG2O|Q>
human HOP62 cells M3\LPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4Owemdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhQWDZ{IHPlcIx{KGK7IH\peoUu\G:|ZTDndo94fGhiaX7obYJqfGmxbjDhd5NigSxiSVO1NF0yOCCwTR?= MWiyOVkxQTJ5OR?=
human MCF7 cells MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlrxS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWNHPyClZXzsd{BjgSCoaY\lMYRwe2ViZ4Lve5RpKGmwaHnibZRqd25iYYPzZZktKEmFNUC9NVAhdk1? MXmyOVkxQTJ5OR?=
human UACC62 cells NFLQW2ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYn4[YxkT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXUGFQ{[yJINmdGy|IHL5JIZqfmVvZH;z[UBoem:5dHigbY5pcWKrdHnvckBie3OjeTygTWM2OD1zMDDuUS=> M1PKSFI2QTB7Mke5
human DU145 cells MlfMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnTCS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSHUyPDViY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCLQ{WwQVExKG6P MoLiNlU6ODl{N{m=
LoVo cell line M3v6[GN6fG:2b4jpZ:Kh[XO|YYm= MXzDfZRwfG:6aXOgdI91\W62aXH0bY9vKG:oIGTvdI91\WOjbjCoWHAqKGK7IITo[UBkd22yb4Xu[EBqdiBqaIXtZY4h[2:ub4LlZ5RidCClYX7j[ZIhVG:YbzDj[YxtKGyrbnWsJGlEPTB;MUGuOkBvVQ>? M{fEWVEzPDB6N{C3
human lymphoblast tumor cell line RPM18402 M3vMO2N6fG:2b4jpZ:Kh[XO|YYm= MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDsfY1xcG:kbHHzeEB1fW2xcjDj[YxtKGyrbnWgVnBOOTh2MEKsJGlEPTB;MUKgcm0> NYfFe4N5OTJ|OUK3OFU>
human HL60 cells NHjj[WdHfW6ldHnvckBie3OjeR?= M3i0fGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZpkhW1KEIH3leIhw\CxiSVO1NF0yOiCwTR?= MVKxPVU1OTR6Mx?=
human A375 cells MUTDfZRwfG:6aXRCpIF{e2G7 NGrwXm04OiCq MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OD1zMzDuUS=> MkLnNlE{PDF4N{S=
COR-L23/P cell NHHYUHlEgXSxdH;4bYPDqGG|c3H5 NYfwNVRHS3m2b4TvfIlkcXS7IH3lZZN2emWmIIXzbY5oKHSqZTDDU3IuVDJ|IIDhdoVvfGGuIDjDU3IuVDJ|L2CpJIh2dWGwIH7vckB{dWGubDDj[YxtKGy3bnegZ4Fz[2mwb33hJINmdGxibHnu[UwhUUN3ME2xN{4zKG6P NIrPOVgyOThyNkeyOC=>
human NCI-H460 cells NEH1RnJRem:uaX\ldoF1cW:wIHHzd4F6 NIXjc|U4OiCq MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDjc5VtfGW{IHPveY51\XJiYX7hcJl{cXNuIFnDOVA:OTZibl2= MVGyNVc5OzN4OR?=
human MOLT4 cells NWT2U|NVS3m2b4TvfIlkyqCjc4PhfS=> NVfEWWY6PzJiaB?= MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNU2xVPCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUG5JI5O MmrjNlQ6ODB5MkW=
human LoVo cells NW\aPVFIS3m2b4TvfIlkyqCjc4PhfS=> MlyyO|IhcA>? MlPoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUI9XdyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUKwJI5O NFfRW5kzODN5MUG4Ny=>
RPM18402 tumor cell line MV7Qdo9tcW[ncnH0bY9vKGG|c3H5 NXLRfVZPS2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JINmdGxicILvcIln\XKjdHnvckBqdiCUUF2xPFQxOiC2dX3vdkBk\WyuIHzpcoUtKEmFNUC9NlAhdk1? NFziNIgyPTR6MkmyPS=>
human SN12C cells MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MonCS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV24yOkNiY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCJSUWwQVIxKG6P NEj6ZYQzPTlyOUK3PS=>
human RPMI8226 cells MWrDfZRwfG:6aXRCpIF{e2G7 MmSwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVnBOUTh{Mk[gZ4VtdHNiYomgUXRVKG2ndHjv[EwhUUN3ME2yNUBvVQ>? NV:5XGoxOTlyMUK5PVY>
HT-29 cells MmPqR5l1d3SxeHnjxsBie3OjeR?= NUjaVmxZS3m2b4TvfIlkcXS7IIfhd{Bl\XSncn3pcoVlKGmwII\peJJwKGmwIFjUMVI6KGOnbHzzLINwdG:wKTDv[kBpfW2jbjD0eY1weiClZXzsJIxqdmW|IHL5JJV{cW6pIF3UWEBie3OjeTygTWM2OD1{NTDuUS=> MYS3PFU{OzNz
SK-BR-3 cells MkP3R5l1d3SxeHnjxsBie3OjeR?= M{[y[mlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIJz\WG|dDDjZY5k\XJiY3XscEBtcW6nIDjTT{1DWi1|KTygTWM2OD1{NjDuUS=> MnX0NVE{OzR3Nkm=
HeLa cells M{fHOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFX6ZmZIem:5dHigbY5pcWKrdHnvckBw\iCKZVzhJINmdGy|IHHmeIVzKDRiZHH5d{whT0l3ME2zNEBvVQ>? M1vaT|E4PDF6NUiy
UACC 62 cells NESySo1EgXSxdH;4bYPDqGG|c3H5 M1zJVXRme3SnZDDpckB3cXS{bzDmc5Ih[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hfHWvb4KgZ4VtdCCuaX7lJHVCS0NiNkKgLI1mdGGwb33hLUwhT0l3ME2zNEBvVQ>? M{PVfVExPzF2NUCy
human HCT116 cells NHjjc2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NG\tXI1Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJS1RzMU[gZ4VtdHNiYomg[ol3\S2mb4PlJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7LDDHTVUxRTNyIH7N NWnsS4RzOjV7MEmyO|k>
human lung cancer cell line (H128) NHzOb2ZEgXSxdH;4bYPDqGG|c3H5 M13udWlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIx2dmdiY3HuZ4VzKGOnbHygcIlv\SBqSEGyPEktKEmFNUC9N|Ehdk1? NF[1N5YyOTN|NEW2PS=>
human MES-SA/Dx5 cells M{j1VWN6fG:2b4jpZ:Kh[XO|YYm= MkfSR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWVUNVODL1T4OUBk\WyuczDveoVz\XiycnXzd4lv\yCPRGKxJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OD1|MzDuUS=> MW[yNVM1OTZ5NB?=
human A2780 cells NIDLTVREgXSxdH;4bYPDqGG|c3H5 MWK3NkBp NFm4dXNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVM{KG6P MmPaNlQ6ODB5MkW=
human MDA-MB-435 cells NVzZXYZjS3m2b4TvfIlkyqCjc4PhfS=> MU[3NkBp MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO1JINmdGy|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KE2WVDDhd5NigSxiR1m1NF0{PCCwTR?= MmXQNlI5PjdyMUm=
human stomach cancer cell line (MKN45) MX3DfZRwfG:6aXRCpIF{e2G7 M2XlZWlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJN1d22jY3igZ4Fv[2W{IHPlcIwhdGmwZTCoUWtPPDVrLDDJR|UxRTN6IH7N NWTkc5hyOTF|M{S1Olk>
human KB3-1 cells MX3DfZRwfG:6aXRCpIF{e2G7 M1fF[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDOy1zIHPlcIx{KGGodHXyJG1VXCCjc4PhfUwhUUN3ME20NEBvVQ>? NVjlN3I6OTh6MkmzN|Q>
mouse P388 cells NUjGepRCS3m2b4TvfIlkyqCjc4PhfS=> Mn7iR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgVFM5QCClZXzsd{Bi\nSncjDNWHQh[XO|YYmsJGlEPTB;NEWgcm0> MkjCNVg5Ojl|M{S=
A427 human lung carcinoma NWHifHF[WHKxbHnm[ZJifGmxbjDhd5NigQ>? NG\6fW5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBu\WG|dYLl[EBi\2GrboP0JGE1OjdiaIXtZY4hdHWwZzDjZZJkcW6xbXGsJGlEPTB;NEmgcm0> NUfMSocxQTh5NkGxNS=>
human U251 cells M2j6VGZ2dmO2aX;uJIF{e2G7 NIHneZo3NTJ2IHi= M4[0eGlvcGmkaYTpc44hd2ZidH;wc4l{d22ncnHz[U0yKGmwIHj1cYFvKFV{NUGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCqeYDvfIliNWmwZIXj[YQhUEmILUHhcJBp[SCjY3P1cZVt[XSrb36gbY4hdnWlbHXhdkBmgHS{YXP0JIFnfGW{IE[geI8hOjRiaILzJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXNuIFXDOVA:PTRibl2= MUSyNlMxPTZzMh?=
human colon cancer cell line (WiDr) Mk[yR5l1d3SxeHnjxsBie3OjeR?= MlOzTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHygcIlv\SBqV3nEdkktKEmFNUC9OVYhdk1? M1qwUlEyOzN2NU[5
human HepG2 cells NX;SSG5XS3m2b4TvfIlkyqCjc4PhfS=> NXvtTWNjPCCmYYnz NEHk[HdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkA1KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVYxKG6P M1X4[VE5PTV2OUC2
human KB cells Mn;oR5l1d3SxeHnjxsBie3OjeR?= MWS3NkBp NYjyUmJuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0JiY3XscJMh[W[2ZYKgO|IhcHK|IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJIF{e2G7LDDJR|UxRTZ{LkWgcm0> M{D0XVI2ODB6NEW2
human HCT8 cells NFWxfZZEgXSxdH;4bYPDqGG|c3H5 NWHIOmpqOyCmYYnz MkLUR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVQCClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUewJI5O MlTCNlA{QTJ3NEW=
human GBM2 cells NYTTTZBWWHKxbHnm[ZJifGmxbjDhd5NigQ>? M{\YPVczKGh? NFnySWVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFfCUVIh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JHdUXC1zIH3leIhw\CxiSVO1NF0xNjF|IN88US=> MkG3NlY{PTV3M{K=
SK-MEL-2 cells M{XLfGN6fG:2b4jpZ:Kh[XO|YYm= NYe3Z2pyPzJiaB?= M2rVOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMNU2HTD2yJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiSVO1NF0xNjF2IN88US=> NGq3[HkzOTN2MU[3OC=>
human IGROV1 cells M2H1R2N6fG:2b4jpZ:Kh[XO|YYm= NI\mVJQ4OiCq MnTvR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTWdTV1ZzIHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME2wMlE3KM7:TR?= M1PRfFIyOzRzNke0
human U87 cells MWfQdo9tcW[ncnH0bY9vKGG|c3H5 M3PNdVQ5KGh? MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV6NzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMU[g{txO NHPoTWozPDh{NkixPC=>
human HT1080 cells MUTQdo9tcW[ncnH0bY9vKGG|c3H5 NWnLbVhIPDhiaB?= NV7TTlFNSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWFExQDBiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygTWM2OD1yLkG4JO69VQ>? MVqyOlQxQDhzNR?=
human Hep3B cells M3PMfHBzd2yrZnXyZZRqd25iYYPzZZk> M{WyPFczKGh? NHXYdHhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldFNDKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDYWHQh[XO|YYmsJGdKPTB;MD6yNkDPxE1? M17VeVE6Pzl4OUW2
human GBM3 cells NUXoSmp6WHKxbHnm[ZJifGmxbjDhd5NigQ>? NImzWWM4OiCq M4X3dGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iR1LNN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgW3NVNTFibXX0bI9lNCCLQ{WwQVAvOzhizszN MVKyOlM2PTV|Mh?=
human KBVIN cells Mke2R5l1d3SxeHnjxsBie3OjeR?= MYG3NkBp M2fWWGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDXkmQIHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE41KM7:TR?= MX:yOVQ{QDd4OR?=
human GBM1 cells NGnYNXpRem:uaX\ldoF1cW:wIHHzd4F6 MkLXO|IhcA>? M4\RRmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iR1LNNUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgW3NVNTFibXX0bI9lNCCLQ{WwQVAvPDZizszN NHz4d2czPjN3NUWzNi=>
human U937 cells MlXkR5l1d3SxeHnjxsBie3OjeR?= NXjHcZAxPDhiaB?= M1rOSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU6OzdiY3XscJMh\XiycnXzd4lv\yCyNUOgcZV1[W62IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[Xli78{MJGlEPTB;MT6xJO69VQ>? MWmxPVcyPTNzOR?=

... Click to View More Cell Line Experimental Data

In vivo Animals inoculate s.c. with DU-145 Luc cells and then treated with Topotecan demonstrates significant tumor growth and regression as measured with calipers and luminescent imaging. The correlation coefficient is 0.75 for the control untreated group and 0.93 for the Topotecan-treated group. Similarly, tumor progression and regression are measurable using luminescent imaging for untreated and Topotecan-treated mice inoculated i.p. with MCF-7 Luc cells. [1] Topotecan elicited potent antileukemic activity in severe combined immune-deficiency (SCID) mouse models of human poor prognosis ALL. Topotecan markedly improved event-free survival of SCID mice challenged with otherwise fatal doses of humaln leukemia cells at systemic drug exposure levels. [2] Gliomas preferentially express TRAIL R2 and that treatment with Topotecan significantly up-regulates its expression. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7 Luc and DU-145 Luc cells
  • Concentrations: 0 μg/mL - 0.692 μg/mL
  • Incubation Time: 96 hours
  • Method:

    Topotecan is dissolved in sterile water to a stock concentration of 1 mg/mL, diluted to 6 μg/mL in cultured medium and then serially diluted 1:4 in opaque, white tissue culture-treated microplates to a final volume of 0.1 mL/well. MCF-7 Luc and DU-145 Luc cells are resuspended in 3×104 cells/mL in DMEM with high glucose containing 10% FBS and 0.5 mg/mL Geneticin; 100 μL of cells are added in each well. Plates are incubated for 4 days at 37 °C in 95% humidity/5% CO2. After incubation, 0.05 mL of 0.1 M HEPES buffer (pH 7.9) containing 50 μg/mL D-luciferin is added to each well. After incubation at room temperature for 10 minutes, the culture microplate is measured in a microplate luminometer and a molecular light imager. Results obtained with the microplate luminometer are calculated using no inhibition control wells without exogenous drug and maximum inhibition control wells containing ATP inhibitor. Results for the molecular light imager are similarly calculated using values obtained with a 5 minutes luminescent imager.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice with MCF-7 Luc or DU-145 Luc cells
  • Formulation: PBS
  • Dosages: 0.25 mg/mL
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL (198.72 mM)
Water 91 mg/mL (198.72 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 457.91
Formula

C23H23N3O5.HCl

CAS No. 119413-54-6
Storage powder
in solvent
Synonyms NSC609699, Nogitecan HCl, SKFS 104864A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03126916 Recruiting Childhood Ganglioneuroblastoma|Childhood Neuroblastoma|INRG Stage L2|INRG Stage M|INRG Stage MS|NMYC Gene Amplification|Recurrent Neuroblastoma Children''s Oncology Group|National Cancer Institute (NCI) May 9 2018 Phase 3
NCT02278510 Completed Malignant Glioma|WHO Grade III or IV Recurrent Glioma Michael Vogelbaum MD PhD|Infuseon Therapeutics Inc.|Case Comprehensive Cancer Center December 9 2014 Early Phase 1
NCT00553189 Completed Solid Tumors|Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2007 Phase 1
NCT03289910 Recruiting Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Atypical Chronic Myeloid Leukemia BCR-ABL1 Negative|Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Myelodysplastic/Myeloproliferative Neoplasm|Myelofibrosis|Polycythemia Vera|Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia National Cancer Institute (NCI) June 8 2018 Phase 2
NCT00158886 Terminated Carcinoma Renal Cell GlaxoSmithKline November 8 2001 Phase 1
NCT00186888 Active not recruiting Retinoblastoma|Retinal Neoplasm St. Jude Children''s Research Hospital|National Cancer Institute (NCI) April 7 2005 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like get the compound for mice intraperitoneally injection, What would you recommend to improve solubility? What could I use as solvent (%v?) that is nontoxic (unlike Methanol) and could be injected into mice intraperitoneally?

  • Answer:

    Topotecan HCl is generally prepared by Saline for I.P. administration.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products0

Tags: buy Topotecan HCl | Topotecan HCl supplier | purchase Topotecan HCl | Topotecan HCl cost | Topotecan HCl manufacturer | order Topotecan HCl | Topotecan HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID